Valuation : Norda ASA

Market Cap 513M 54.91M 47.28M 44.39M 40.52M 76.12M 5.22B 76.67M 526M 205M 2.65B 206M 202M 8.77B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.29M 24.35M 22.87M 20.87M 39.21M 2.69B 39.5M 271M 105M 1.36B 106M 104M 4.52B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day-1.62%
1 week-1.62%
Current month-1.62%
1 month-1.62%
3 months-1.62%
6 months-0.12%
Current year-15.00%
1 week 85
Extreme 85
85
1 month 85
Extreme 85
85
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 07/04/2013
Director TitleAgeSince
Chairman 54 30/01/2014
Director/Board Member 68 19/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-1.62%+4.94%+107.32% 46.67M
+0.14%-1.74%+1.16%+18.14% 49.81B
-1.11%-2.84%+420.04%+505.15% 44.06B
-0.21%+0.37%+36.88%+17.32% 42.99B
-1.95%-3.33%+8.29%+73.25% 40.88B
-0.94%-1.77%+18.34%+46.84% 33.11B
-1.11%-4.20%+25.49%+119.78% 16.58B
+6.10%+4.40% - - 17.27B
+0.91%-1.19%+12.65%+29.24% 14.63B
-1.12%-3.46%+76.50%+39.37% 13.76B
Average -0.09%-1.23%+67.14%+106.27% 27.31B
Weighted average by Cap. -0.28%-1.49%+88.94%+122.76%

Financials

2023 2024
Net sales 86.92M 9.3M 8.01M 7.52M 6.86M 12.89M 885M 12.99M 89.1M 34.67M 449M 34.92M 34.16M 1.49B 372M 39.79M 34.26M 32.17M 29.36M 55.16M 3.79B 55.56M 381M 148M 1.92B 149M 146M 6.36B
Net income 31.17M 3.34M 2.87M 2.7M 2.46M 4.62M 317M 4.66M 31.95M 12.43M 161M 12.52M 12.25M 533M 126M 13.48M 11.6M 10.89M 9.95M 18.68M 1.28B 18.82M 129M 50.23M 650M 50.6M 49.5M 2.15B
Net Debt -311M -33.3M -28.67M -26.92M -24.58M -46.17M -3.17B -46.5M -319M -124M -1.61B -125M -122M -5.32B -249M -26.62M -22.92M -21.52M -19.65M -36.91M -2.53B -37.17M -255M -99.23M -1.28B -99.96M -97.79M -4.25B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. NORD Stock